Clinical pharmacokinetics and pharmacodynamics of aliskiren

Clinical Pharmacokinetics

Volumn 47, Issue 8, 2008, Pages 515-531

  Vaidyanathan, Sujata ^a   Jarugula, Venkateswar ^a   Dieterich, Hans Armin ^a   Howard, Dan ^a   Dole, William P ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Aliskiren, pharmacodynamics; Aliskiren, pharmacokinetics; Antihypertensives, pharmacodynamics; Antihypertensives, pharmacokinetics; Clinical pharmacokinetics; Drug interactions; Liver dysfunction; Pharmacokinetic pharmacodynamic relationships

Indexed keywords

ACENOCOUMAROL; ALISKIREN; ALLOPURINOL; AMLODIPINE; ATENOLOL; ATORVASTATIN; CAPTOPRIL; CELECOXIB; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FENOFIBRATE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; METFORMIN; MEVINOLIN; PIOGLITAZONE; RAMIPRIL; VALSARTAN; WARFARIN;

ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AMIDES; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FUMARATES; HUMANS; HYPERTENSION; RENIN;

EID: 47049089844     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847080-00002     Document Type: Review

References (68)

1. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12 (12 Pt 3): 205S-13S
2. Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003; 21 (9): 1599-608
3. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005; 16 (3): 592-9
4. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24 (2): 243-56
5. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80 (2): 219-27
6. Kahn JR, Lentz K, Skeggs Jr LT, et al. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106 (3): 439-53
7. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308 (4): 698-705
8. Lefèvre G, Duval M, Poncin A. Direct micro-radioimmunoassay of the new renin inhibitor CGP 60536. J Immunoassay 2000; 21 (1): 65-84
9. Vaidyanathan S, Warren V, Yeh C-M, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47 (2): 192-200
10. Vaidyanathan S, Reynolds C, Yeh C-M, et al. The pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with the P-glycoprotein modulators ketoconazole, digoxin and atorvastatin in healthy subjects [abstract no. PIII-175]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S109
11. Vaidyanathan S, Reynolds C, Yeh C-M, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47 (4): 453-60
12. Vaidyanathan S, Jermany J, Yeh C-M, et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 62 (6): 690-8
13. Nussberger J, Jensen C. The bioavailability of aliskiren (SPP100) administered as 2 x 37.5mg capsules and a 75mg oral solution compared to a 20mg intravenous administration in healthy male subjects. Basel: Speedel Pharma AG, 2001. (Data on file)
14. Vaidyanathan S, Limoges D, Yeh C-M, et al. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers [abstract no. PIII-23]. Clin Pharmacol Ther 2006; 79 (2 Suppl. S): P64
15. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006; 60 (11): 1343-56
16. Reynolds C, Vaidyanathan S, Dieterich H-A, et al. A randomized, open-label, single-dose, two-period, crossover study in healthy subjects to evaluate the effect of food on the SPP100 Final Market Image (FMI) tablet. Basel: Novartis Pharma AG, 2006. (Data on file)
17. Mann J, Dieterle W. Aliskiren: a phase I, open-label, randomised, balanced, three-period crossover single oral dose study to investigate the comparative bioavailability of two different formulations and the effect of food on the pharmacokinetics in healthy male and female subjects. Basel: Speedel Pharma AG, 2002. (Data on file)
18. Tekturna® (aliskiren) tablets 150 mg and 300 mg [US prescribing information; online]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2007 Dec. Available from URL: http://www.tekturna.com/index.jsp?usertrack. filter_applied=true&NovaId=1137599007196 [Accessed 2008 May 27]
19. Rasilez [EU summary of product characteristics; online]. Horsham: Novartis Europharm Limited, 2007 Sep 3. Available from URL: http://www.emea. europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm [Accessed 2008 May 27]
20. Waldmeier FJ, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35 (8): 1418-28
21. Data on file, Novartis Pharmaceuticals Corporation, 2007
22. Jin Y, Borell H. Identification of human cytochrome P450 enzymes involved in the oxidative metabolism of SPP100 (aliskiren). Basel: Novartis Pharma AG, 2005. (Data on file)
23. Vaidyanathan S, Bigler H, Yeh C-M, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46 (8): 661-75
24. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15 (12): 3126-33
25. Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43 (11): 527-35
26. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39 (1): E1-8
27. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49 (11): 1157-63
28. Weir MR, Bush C, Anderson DR, et al. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007; 1 (4): 264-77
29. Data on file, Novartis Pharmaceuticals Corporation, 2006
30. Zhao C, Vaidyanathan S, Yeh C-M, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with diabetes. Clin Pharmacokinet 2006; 45 (11): 1125-34
31. Vaidyanathan S. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro [abstract]. Basic Res Pharmcol Toxicol 2005; 97 Suppl. 1: 239
32. Camenisch G. Determination of the interaction with the human MDR1, MRP2 and BCRP (MXR) transporters using the ATPase assay. Basel: Novartis Pharma AG, 2004. (Data on file)
33. Dieterich H-A, Warren V, Sabo R, et al. Lack of pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and pioglitazone or fenofibrate in healthy volunteers [abstract no. P220]. Basic Clin Pharmcol Toxicol 2007; 101 Suppl. 1: 135-6
34. Reynolds C, Vaidyanathan S, Dieterich H-A, et al. Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers [abstract no. PIII-177]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S110
35. Urosevic D, Bartlett M, Costa AM, et al. Lack of pharmacokinetic interaction between aliskiren a direct oral renin inhibitor and isosorbide-5-mononitrate in healthy volunteers [abstract no. P032]. Basic Clin Pharmacol Toxicol 2007; 101 Suppl. 1: 63
36. Zhao C, Vaidyanathan S, Dieterich H-A, et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract no. PIII-178]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S110
37. Ayalasomayajula S, Tchaloyan S, Yeh C-M, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008; 24 (3): 717-20
38. Achira M, Suzuki H, Ito K, et al. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1999; 1 (4): E18
39. Sakaeda T, Fujino H, Komoto C, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006; 23 (3): 506-12
40. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111 (8): 1012-8
41. Hariry S, Rebello S, Feng A, et al. An open-label, single-dose study to evaluate the pharmacokinetics, safety and tolerability of SPP100 (aliskiren) when given alone and in combination with cyclosporine to healthy subjects. Basel: Novartis Pharma AG, 2007. (Data on file)
42. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 58 (4): 433-6
43. Homsy W, Marleau S, du Souich P. Furosemide dynamics in conscious rabbits: modulation by angiotensin II. Cardiovasc Drugs Ther 1995; 9 (2): 311-7
44. Bindschedler M, Degen P, Flesch G, et al. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997; 52 (5): 371-8
45. Jeunemaitre X, Menard J, Nussberger J, et al. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens 1989; 2 (11 Pt 1): 819-27
46. DiaSorin. RENCTK assay information. Stillwater (MN): DiaSorin Inc., 2007
47. Nussberger J, Porchet M, Fasanella d'Amore T, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987; 9 (1): 39-44
48. Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61 (9): 1461-8
49. Menard J, Guyene TT, Peyrard S, et al. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006; 24 (3): 529-34
50. Lijnen P, Fagard R, Staessen J, et al. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 1981; 12 (3): 387-92
51. Taylor AA, Anderson DR, Arora V, et al. Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension [abstract no. 1014-170]. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 370A
52. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25 (1): 217-26
53. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370 (9583): 221-9
54. Alderman MH, Cohen HW, Sealey JE, et al. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17 (1): 1-7
55. Frandsen E, Boomsma F, Persson F, et al. Aliskiren reduces renin system activity in patients with hypertension, type 2 diabetes and albuminuria [abstract]. American Society of Hypertension 23rd Annual Scientific Meeting; 2008 May 14-17; New Orleans (LA)
56. Feldman DL, Persohn E, Schutz H, et al. Renal localization of the renin inhibitor aliskiren [abstract no. P-78]. J Clin Hypertens 2006; 8 (5): A80-1
57. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42 (6): 1137-43
58. Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke 1998; 29 (5): 992-6
59. Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79 (11): 1512-6
60. Pool JL, Gradman AH, Kolloch R, et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension [abstract no. P-790]. Eur Heart J 2006; 27: 119
61. Keefe DL, Andersen K, Weinberger MH, et al. Blood pressure lowering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibitor [abstract no. P-1014-204]. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 372A
62. Weinberger MH, Andersen K, Constance CM, et al. Aliskiren-based therapy provides long-term suppression of plasma renin activity that persists after treatment withdrawal in patients with hypertension [abstract no. P-1020-168]. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 390A-1A
63. Fisher ND, Hollenberg NK. Unprecedented renal responses to direct blockade of the renin-angiotensin-system with aliskiren, a novel renin inhibitor [abstract]. Circulation 2007; 116 (16 Suppl.): II-556
64. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effect of direct renin inhibition with aliskiren in patients with type 2 diabetes and albuminuria [abstract no. F-PO1029]. J Am Soc Nephrol 2007; 18: 329A
65. Fisher NDL, Danser AHJ, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117 (25): 3199-205
66. Parving H-H, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 2008; 358 (23): 2433-46
67. McMurray JJV, Pitt, B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24
68. Parving HH, Brenner BM, McMurray JJV, et al. ALiskiren Trial In Type 2 diabetes Using cardio-renal Disease Endpoints (ALTITUDE): rationale and study design [abstract no. PUB557]. J Am Soc Nephrol 2007; 18 (Abstracts Issue): 952